Image abnormal brain protein deposits
- Trial ID
- NCT06303921
- Official Title
- Center Without Walls for Imaging Proteinopathies With PET (CW2IP2): Phase I Pilot Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-M503
- Goal
- Image abnormal brain protein deposits
- Phase
- EARLY_PHASE1
- Status
- RECRUITING
- Sponsor
- University of Pennsylvania
- Study Type
- INTERVENTIONAL
- Enrollment
- 70 participants
- Conditions
- Tauopathies
- Interventions
- 11C-M503 PET, Brain MRI, Amyloid PET, Neurological assessments
Plain-Language Summary
Goal: The team is testing whether a new PET tracer, 11C-M503, can safely reach the brain and highlight abnormal protein deposits like tau that are linked to PSP, MSA, and other tauopathies. Approach: Participants will have PET scans with 11C-M503 plus MRI, amyloid PET and neurological exams while researchers measure how the tracer is distributed, metabolized, excreted, and taken up in the brain; 11C-M503 is a radioactive imaging ligand meant to reveal protein aggregates and is diagnostic only, so it should not affect treatments like levodopa. Eligibility: Adults aged 40 to 85 are being enrolled, including people with clinical diagnoses of Parkinson disease, MSA, PSP, and healthy controls, who can provide consent or have a study partner; pregnant or breastfeeding women are excluded.
Locations
- Yale New Haven Hospital, New Haven, Connecticut, United States
- Washington University in St. Louis, St Louis, Missouri, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
Frequently Asked Questions
- What is this trial testing?
- This trial is studying 11C-M503 PET. Goal: The team is testing whether a new PET tracer, 11C-M503, can safely reach the brain and highlight abnormal protein deposits like tau that are linked to PSP, MSA, and other tauopathies. Approach: Participants will have PET scans with 11C-M503 plus MRI, amyloid PET and neurological exams while researchers measure how the tracer is distributed, metabolized, excreted, and taken up in the brain; 11C-M503 is a radioactive imaging ligand meant to reveal protein aggregates and is diagnostic only, so it should not affect treatments like levodopa. Eligibility: Adults aged 40 to 85 are being enrolled, including people with clinical diagnoses of Parkinson disease, MSA, PSP, and healthy controls, who can provide consent or have a study partner; pregnant or breastfeeding women are excluded.
- Who can participate?
- Participants must be between 40 Years and 85 Years.
- Where is this trial located?
- This trial is recruiting at 3 locations.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This Phase 1 trial is estimated to last approximately 5 years.